# To Assess the Safety, Immunogenicity and Efficacy of VLPM01 in Healthy, Malaria-Naïve Volunteers

> **NCT03867331** · PHASE1 · COMPLETED · sponsor: **VLP Therapeutics** · enrollment: 36 (actual)

## Conditions studied

- Malaria,Falciparum

## Interventions

- **BIOLOGICAL:** 5 microgram VLPM01
- **BIOLOGICAL:** 15 microgram VLPM01
- **BIOLOGICAL:** 30 microgram VLPM01
- **OTHER:** Plasmodium falciparum challenge

## Key facts

- **NCT ID:** NCT03867331
- **Lead sponsor:** VLP Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-13
- **Primary completion:** 2020-05-21
- **Final completion:** 2020-05-21
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03867331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03867331, "To Assess the Safety, Immunogenicity and Efficacy of VLPM01 in Healthy, Malaria-Naïve Volunteers". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03867331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*